Boston Scientific Redraws U.S. Sales Map, Adds 25% More Taxus Reps
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific plans to halt the decline of its U.S. drug-eluting stent market share by expanding its domestic interventional cardiology sales force by about 25% in the third quarter
You may also be interested in...
Boston Scientific Loses Share To J&J; Rebate Program Could Buoy Sales
Boston Scientific's share of the U.S. drug-eluting stent market fell four percentage points to 55% during the third quarter as the firm failed to stop Johnson & Johnson/Cordis from stealing market share
Boston Scientific Loses Share To J&J; Rebate Program Could Buoy Sales
Boston Scientific's share of the U.S. drug-eluting stent market fell four percentage points to 55% during the third quarter as the firm failed to stop Johnson & Johnson/Cordis from stealing market share
Cypher Edges Out Taxus In A Meta-Analysis Of Six Head-To-Head Trials
A meta-analysis of six drug-eluting stent trials suggests that sirolimus-elutings stents are associated with a lower risk of restenosis and target vessel revascularization than paclitaxel-eluting stents